N Bouaziz, C Michiels, D Janssens, N Berna, F Eliaers, E Panconi, J Remacle
Index: Int. Angiol. 18(4) , 306-12, (1999)
Full Text: HTML
Ruscus aculeatus extract and the flavonoid hesperidin methylchalcone (HMC) are drugs used in the treatment of chronic venous insufficiency.In the present study, we investigated their effects on the activation of endothelial cells by hypoxia, a condition which mimics venous blood stasis.We observed that Ruscus extract was able to inhibit the activation of endothelial cells by hypoxia: the decrease in ATP content, the activation of phospholipase A2 as well as the subsequent increase in neutrophil adherence with a maximal protection obtained at 50 microg/ml. HMC was also able to inhibit the hypoxia-induced decrease in ATP content. Furthermore, the effects of Ruscus extract and of HMC on this decrease seem to be additive.The biochemical mechanism evidenced in this work might explain some of the beneficial therapeutic effects of these products in the treatment of chronic venous insufficiency patients.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Hesperidin methylchalcone
CAS:24292-52-2 |
C29H36O15 |
Assessment of the antineoplastic potential of chalcones in a...
2013-01-01 [Curr. Med. Chem. 20(2) , 186-221, (2013)] |
Absorption and elimination of (14C) hesperidin methylchalcon...
1981-01-01 [Eur. J. Drug Metab. Pharmacokinet. 6(3) , 171-7, (1981)] |
Inhibitory effect of the Ruscus extract and of the flavonoid...
1993-08-01 [J. Cardiovasc. Pharmacol. 22(2) , 225-30, (1993)] |
Hesperidin, hesperidin methyl chalone and phellopterin from ...
2008-05-01 [Int. Immunopharmacol. 8(5) , 670-8, (2008)] |
Clinical and capillaroscopic evaluation in the treatment of ...
2007-12-01 [Int. Angiol. 26(4) , 378-84, (2007)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved